Jupiter Neurosciences, Inc. (JUNS)

US — Healthcare Sector

Peers:

Automate Your Wheel Strategy on JUNS

With Tiblio's Option Bot, you can configure your own wheel strategy including JUNS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol JUNS
Rev/Share 0.0
Book/Share 0.0404
PB 36.7682
Debt/Equity 0.1439
CurrentRatio 1.0727
ROIC -3.754

MktCap 51651791.0
FreeCF/Share -0.1697
PFCF -9.175
PE -8.3508
Debt/Assets 0.0486
DivYield 0
ROE -8.3525

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 1
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

JUNS
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio

image for news Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

JUNS
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation

About Jupiter Neurosciences, Inc. (JUNS)

IPO Date 2022-01-18
Website https://www.jupiterorphan.com
Industry Biotechnology
CEO Christer Rosen
Employees 4

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.